Altimmune, Inc.
ALTNASDAQHealthcare● Active
$2.71
$-0.00(-0.05%)
Market Cap$239053723
P/E Ratio—
52W High$7.73
52W Low$2.56
Altimmune, Inc. (ALT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.18
Est. -$0.25 · +28.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ALT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.17 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.25 | -$0.18 | +28.0% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.25 | -$0.27 | -8.0% | $0.00B | $0.00B | +4576.3% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.29 | -$0.21 | +27.6% | $0.00B | $0.00B | +792.9% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.32 | -$0.27 | +15.6% | $0.00B | $0.00B | +249.9% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.35 | -$0.26 | +25.7% | $0.00B | $0.00B | +792.9% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.34 | -$0.33 | +2.9% | $0.00B | $0.00B | +400.0% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.36 | -$0.32 | +11.1% | $0.00B | $0.00B | +600.3% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.25
EPS Surpr.
+28.0%
Revenue
—
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.27
EPS Est.
-$0.25
EPS Surpr.
-8.0%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.29
EPS Surpr.
+27.6%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.27
EPS Est.
-$0.32
EPS Surpr.
+15.6%
Revenue
$0.00B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$0.35
EPS Surpr.
+25.7%
Revenue
$0.00B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.34
EPS Surpr.
+2.9%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.32
EPS Est.
-$0.36
EPS Surpr.
+11.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.30 | $-0.30 | $-0.30 | 2 |
| Q3 FY2028 | $-0.30 | $-0.30 | $-0.30 | 2 |
| Q2 FY2028 | $-0.30 | $-0.30 | $-0.30 | 2 |
| Q1 FY2028 | $-0.30 | $-0.30 | $-0.30 | 2 |
| Q4 FY2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q3 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +28.0% | $3.08 | $3.02 | -1.95% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -8.0% | $4.27 | $3.51 | -17.80% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +27.6% | $3.75 | $3.94 | +5.07% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +15.6% | $3.38 | $3.62 | +7.10% |
| ▲ Q2 FY2025 | May 13, 2025 | +25.7% | $6.01 | $5.76 | -4.16% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +2.9% | $5.94 | $6.42 | +8.08% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +11.1% | $7.35 | $9.49 | +29.12% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -2.9% | $5.50 | $6.33 | +15.09% |
Q2 FY2026-1.95%
Report Date
May 13, 2026
EPS Beat/Miss
+28.0%
Price Before
$3.08
Price After
$3.02
Q1 FY2026-17.80%
Report Date
Mar 5, 2026
EPS Beat/Miss
-8.0%
Price Before
$4.27
Price After
$3.51
Q4 FY2025+5.07%
Report Date
Nov 6, 2025
EPS Beat/Miss
+27.6%
Price Before
$3.75
Price After
$3.94
Q3 FY2025+7.10%
Report Date
Aug 12, 2025
EPS Beat/Miss
+15.6%
Price Before
$3.38
Price After
$3.62
Q2 FY2025-4.16%
Report Date
May 13, 2025
EPS Beat/Miss
+25.7%
Price Before
$6.01
Price After
$5.76
Q1 FY2025+8.08%
Report Date
Feb 27, 2025
EPS Beat/Miss
+2.9%
Price Before
$5.94
Price After
$6.42
Q4 FY2024+29.12%
Report Date
Nov 12, 2024
EPS Beat/Miss
+11.1%
Price Before
$7.35
Price After
$9.49
Q3 FY2024+15.09%
Report Date
Aug 8, 2024
EPS Beat/Miss
-2.9%
Price Before
$5.50
Price After
$6.33
Avg Beat Reaction+7.21%
Avg Miss Reaction-1.36%
Beat Rate6 / 8 quarters
Largest Move+29.12% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALT ends December
Altimmune, Inc. (ALT) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.18 — beating the analyst consensus of $-0.25 by +28.0%. The next ALT earnings date is expected around September 1, 2026.
Each quarter, investors track ALT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALT earnings · 5 questionsAltimmune, Inc.'s next earnings report is expected around September 1, 2026. ALT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALT historically reports after market close (AMC).
ALT earnings datewhen is ALT earningsALT next earnings datewhen does ALT report earningsALT earnings calendar
▸ Source: FMP · Altimmune, Inc. SEC filings · US GAAP · Altimmune, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026